Mineralys Therapeutics had its Relative Strength (RS) Rating upgraded from 90 to 94 Tuesday.
IBD's unique rating measures market leadership with a 1 (worst) to 99 (best) score. The score shows how a stock's price behavior over the last 52 weeks stacks up against all the other stocks in our database.
History reveals that the top-performing stocks typically have an 80 or higher RS Rating as they begin their biggest climbs.
Here Are 3 Keys For Successful Stock Investing
Mineralys Therapeutics broke out earlier, but is now around 3% below the prior 15.25 entry from a consolidation. If a stock you're tracking clears a buy point then retreats 7% or more below the original entry price, it's considered a failed base. It's best to wait for the stock to form a new consolidation and breakout. Also understand that the most recent pattern is a later-stage base, and such bases are more prone to failure.
The company showed 0% earnings growth in the latest quarterly report, while sales growth came in at 0%.
Mineralys Therapeutics earns the No. 79 rank among its peers in the Medical-Biomed/Biotech industry group. Krystal Biotech, ADMA Biologics and Catalyst Pharmaceuticals are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
IBD Stock Rating Upgrades: Rising Relative Strength
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
